The non-invasive test targets predicting amnestic mild cognitive impairment (aMCI), where memory loss is the main symptom. Credit: Darmiyan / PRNewswire.

Darmiyan has launched the BrainSee Platform, featuring the US Food and Drug Administration (FDA) approved BrainSee test for Alzheimer’s disease.

This marks a significant advancement in the diagnosis and monitoring of Alzheimer’s dementia risk, particularly for patients with amnestic mild cognitive impairment (aMCI).

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

In January this year, the FDA approved BrainSee, a software as a service (SaaS) platform that is poised to transform the approach to evaluating and tracking the likelihood of progression to Alzheimer’s dementia within five years.

The BrainSee test offers a departure from conventional Alzheimer’s assessments that typically depend on non-specific biomarkers such as amyloid or tau.

It is entirely non-invasive, has high accuracy, and targets prognosing aMCI, where memory loss is the primary symptom.

See Also:

Darmiyan founding CEO Dr Padideh Kamali-Zare said: “With the BrainSee Platform, we are excited to offer a comprehensive infrastructure that, in addition to administering BrainSee Test, supports remote doctor visits and consultations, comprehensive cognitive assessments, MRI prescriptions, and follow-ups—all covered under Medicare with just a nominal out-of-pocket booking fee.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Utilising AI algorithms, the BrainSee test analyses routine clinical brain MRIs and cognitive test outcomes. It generates a numerical score from zero to 100, reflecting the patient’s risk of developing Alzheimer’s dementia within five years.

Scores under 50 indicate a low risk, providing patients with peace of mind, while scores above 50 signal a high risk, prompting early intervention and lifestyle changes to potentially avert or delay dementia.

Doctors may opt to repeat the test yearly or more frequently based on their discretion, to track risk alterations and evaluate the effectiveness of medical treatments and lifestyle adjustments in shifting a patient’s risk status from high to low.

From this month, healthcare providers across the US will have access to the BrainSee Platform, offering a new tool in the fight against Alzheimer’s disease.